366 related articles for article (PubMed ID: 25954851)
1. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
[TBL] [Abstract][Full Text] [Related]
2. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
4. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
5. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
[TBL] [Abstract][Full Text] [Related]
7. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
[TBL] [Abstract][Full Text] [Related]
8. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
9. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
[TBL] [Abstract][Full Text] [Related]
10. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Hirooka Y; Goto H
J Med Virol; 2018 Apr; 90(4):736-744. PubMed ID: 29111616
[TBL] [Abstract][Full Text] [Related]
13. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Yoshida K; Hai H; Tamori A; Teranishi Y; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467359
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
[TBL] [Abstract][Full Text] [Related]
17. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
[TBL] [Abstract][Full Text] [Related]
18. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
[TBL] [Abstract][Full Text] [Related]
20. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
